Pascal Schneider Selected Research

B-Cell Activating Factor

1/2021	Function, occurrence and inhibition of different forms of BAFF.
9/2020	Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.
1/2020	B-Cell Activating Factor Secreted by Neutrophils Is a Critical Player in Lung Inflammation to Cigarette Smoke Exposure.
11/2018	B Cell-Activating Factor Neutralization Aggravates Atherosclerosis.
1/2018	Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
1/2016	Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia.
1/2015	B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis.
7/2009	Cracking the BAFF code.
7/2008	Intestinal bacteria condition dendritic cells to promote IgA production.
1/2004	TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pascal Schneider Research Topics

Disease

20	Neoplasms (Cancer) 01/2020 - 08/2003
12	Anhidrotic Ectodermal Dysplasia 1 01/2022 - 11/2007
10	Inflammation (Inflammations) 01/2022 - 01/2004
9	Infections 01/2022 - 01/2002
8	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 01/2004
7	Necrosis 07/2009 - 01/2002
6	Autoimmune Diseases (Autoimmune Disease) 09/2020 - 09/2008
4	Ectodermal Dysplasia (Aplasia Cutis Congenita) 02/2014 - 11/2007
3	Breast Neoplasms (Breast Cancer) 01/2020 - 03/2013
3	Eczema 02/2015 - 11/2006
2	Peritonitis 01/2022 - 07/2009
2	Hypotrichosis 01/2021 - 09/2009
2	Atherosclerosis 01/2021 - 11/2018
2	Pneumonia (Pneumonitis) 01/2020 - 01/2018
2	Melanoma (Melanoma, Malignant) 01/2020 - 10/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 01/2013
2	Fibrosis (Cirrhosis) 01/2018 - 01/2015
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017 - 01/2007
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2017 - 02/2006
2	Common Variable Immunodeficiency 04/2014 - 05/2011
2	Carcinogenesis 04/2013 - 11/2012
2	Dermatitis 11/2006 - 07/2005
1	Endotoxemia 01/2022
1	COVID-19 01/2022
1	Otitis Externa 01/2022
1	Dementia (Dementias) 12/2021
1	Alzheimer Disease (Alzheimer's Disease) 12/2021
1	Atherosclerotic Plaque (Atheroma) 01/2021
1	Anodontia (Hypodontia) 01/2021
1	Hypohidrosis 01/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Cicatrix (Scar) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Lung Injury 01/2020
1	Osteolysis 02/2019
1	Autoimmune Lymphoproliferative Syndrome 01/2019
1	Multiple Sclerosis 01/2019
1	Coronary Disease (Coronary Heart Disease) 11/2018
1	IgA Deficiency 01/2018
1	Non-alcoholic Fatty Liver Disease 01/2018
1	Hyperthermia 01/2018
1	Fatty Liver 01/2018
1	Cleft Palate (Palate, Cleft) 10/2017
1	Neuroinflammatory Diseases 09/2017

Drug/Important Bio-Agent (IBA)

23	LigandsIBA 01/2022 - 01/2002
11	EctodysplasinsIBA 01/2021 - 10/2004
10	B-Cell Activating FactorIBA 01/2021 - 01/2004
8	AntibodiesIBA 01/2022 - 09/2011
8	CytokinesIBA 01/2021 - 11/2006
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 01/2004
5	Edar ReceptorIBA 01/2022 - 10/2004
4	InflammasomesIBA 01/2022 - 07/2009
4	Death Domain ReceptorsIBA 01/2019 - 01/2002
4	AntigensIBA 01/2018 - 07/2009
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2012
3	ChemokinesIBA 01/2020 - 11/2006
3	Denosumab FDA Link 02/2019 - 01/2013
3	TNF-Related Apoptosis-Inducing LigandIBA 01/2017 - 09/2006
3	CaspasesIBA 03/2013 - 01/2002
2	LipopolysaccharidesIBA 01/2022 - 09/2007
2	Neutralizing AntibodiesIBA 09/2020 - 02/2019
2	IntegrinsIBA 01/2020 - 09/2017
2	B-Cell Activation Factor ReceptorIBA 11/2018 - 04/2014
2	CalciumIBA 11/2018 - 05/2011
2	Cyclophilins (Cyclophilin)IBA 11/2018 - 05/2011
2	Monoclonal AntibodiesIBA 01/2018 - 02/2014
2	TWEAK ReceptorIBA 09/2015 - 07/2011
2	Blocking AntibodiesIBA 02/2014 - 01/2002
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 07/2011 - 09/2007
2	Fas Ligand Protein (Fas Ligand)IBA 01/2008 - 11/2006
1	EnrofloxacinIBA 01/2022
1	Uric Acid (Urate)IBA 01/2022
1	AcetylcholinesteraseIBA 12/2021
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 12/2021
1	Tumor Necrosis Factor Ligand Superfamily Member 13IBA 01/2021
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 01/2021
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021
1	ibrutinibIBA 09/2020
1	idelalisibIBA 09/2020
1	venetoclaxIBA 09/2020
1	belimumabIBA 09/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	SmokeIBA 01/2020
1	Cell Adhesion MoleculesIBA 01/2020
1	Purinergic P2X7 ReceptorsIBA 01/2020
1	SyndecansIBA 01/2020
1	Syndecan-4IBA 01/2020
1	Ectodysplasin ReceptorsIBA 01/2019
1	Apolipoproteins E (ApoE)IBA 11/2018
1	TACI receptor-IgG Fc fragment fusion proteinIBA 01/2018
1	Chimeric Antigen ReceptorsIBA 01/2018
1	Immunoglobulin G (IgG)IBA 01/2018
1	Immunoglobulin A (IgA)IBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	EpitopesIBA 01/2018

Therapy/Procedure

7	Therapeutics 01/2018 - 09/2006
3	Immunotherapy 11/2018 - 09/2008
1	Immunomodulation 01/2019